In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: Antinociceptive activity without cannabimimetic side effects

British Journal of Pharmacology

Volumn 171, Issue 6, 2014, Pages 1392-1407

  Ignatowska Jankowska, B M ^a   Ghosh, S ^a   Crowe, M S ^b   Kinsey, S G ^b   Niphakis, M J ^c   Abdullah, R A ^a   Tao, Q ^a   O'Neal, S T ^a   Walentiny, D M ^a   Wiley, J L ^d   Cravatt, B F ^c   Lichtman, A H ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d RTI INTERNATIONAL   (United States)

Author keywords

2 arachidonoylglycerol; allodynia; cannabinoid; gastric haemorrhage; inflammatory pain; monoacylglycerol lipase; mouse; neuropathic pain

Indexed keywords

1,1,1,3,3,3 HEXAFLUOROPROPAN 2 YL 4 [BIS(BENZO[D][1,3]DIOXOL 5 YL)(HYDROXY)METHYL]PIPERIDINE 1 CARBOXYLATE; 2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; ARACHIDONIC ACID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; ENZYME INHIBITOR; FATTY ACID AMIDASE; KML 29; UNCLASSIFIED DRUG;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; BODY TEMPERATURE; CATALEPSY; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERANCE; ENZYME INHIBITION; FEMALE; HYPOTHERMIA; IN VIVO STUDY; INFLAMMATORY PAIN; LOCOMOTION; MALE; MOUSE; NEUROPATHIC PAIN; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; REPEATED DRUG DOSE; STOMACH HEMORRHAGE; STOMACH PROTECTION;

2-ARACHIDONOYLGLYCEROL; ALLODYNIA; CANNABINOID; CB1; CB2; GASTRIC HAEMORRHAGE; INFLAMMATORY PAIN; MONOACYLGLYCEROL LIPASE; MOUSE; NEUROPATHIC PAIN;

ANALGESICS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRAIN; CANNABINOIDS; CHROMATOGRAPHY, LIQUID; ENZYME INHIBITORS; MALE; MICE; MICE, INBRED C57BL; MOLECULAR MIMICRY; MONOACYLGLYCEROL LIPASES; TANDEM MASS SPECTROMETRY;

EID: 84893349761     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12298     Document Type: Article

References (63)

1. Ahn K, McKinney MK, Cravatt BF, (2008). Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev 108: 1687-1707. (Pubitemid 351796405)
2. Ahn K, Johnson DS, Cravatt BF, (2009a). Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders. Expert Opin Drug Discov 4: 763-784.
3. Ahn K, Johnson DS, Mileni M, Beidler D, Long JZ, McKinney MK, et al. (2009b). Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem Biol 16: 411-420.
4. Ahn K, Smith SE, Liimatta MB, Beidler D, Sadagopan N, Dudley DT, et al. (2011). Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain. J Pharmacol Exp Ther 338: 114-124.
5. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Catterall WA, Spedding M, Peters JA, Harmar AJ, and CGTP Collaborators (2013). The Concise Guide to PHARMACOLOGY 2013/14: Overview. Br J Pharmacol 170: 1449-1867.
6. Blankman JL, Simon GM, Cravatt BF, (2007). A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol 14: 1347-1356. (Pubitemid 350257008)
7. Booker L, Kinsey SG, Abdullah RA, Blankman JL, Long JZ, Ezzili C, et al. (2012). The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice. Br J Pharmacol 165: 2485-2496.
8. Burston JJ, Sim-Selley LJ, Harloe JP, Mahadevan A, Razdan RK, Selley DE, et al. (2008). N-arachidonyl maleimide potentiates the pharmacological and biochemical effects of the endocannabinoid 2-arachidonylglycerol through inhibition of monoacylglycerol lipase. J Pharmacol Exp Ther 327: 546-553.
9. Busquets-Garcia A, Puighermanal E, Pastor A, de la Torre R, Maldonado R, Ozaita A, (2011). Differential role of anandamide and 2-arachidonoylglycerol in memory and anxiety-like responses. Biol Psychiatry 70: 479-486.
10. Chanda PK, Gao Y, Mark L, Btesh J, Strassle BW, Lu P, et al. (2010). Monoacylglycerol lipase activity is a critical modulator of the tone and integrity of the endocannabinoid system. Mol Pharmacol 78: 996-1003.
11. Chang JW, Niphakis MJ, Lum KM, Cognetta AB 3rd, Wang C, Matthews ML, et al. (2012). Highly selective inhibitors of monoacylglycerol lipase bearing a reactive group that is bioisosteric with endocannabinoid substrates. Chem Biol 19: 579-582.
12. Chang L, Luo L, Palmer JA, Sutton S, Wilson SJ, Barbier AJ, et al. (2006). Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms. Br J Pharmacol 148: 102-113. (Pubitemid 43675605)
13. Clapper JR, Moreno-Sanz G, Russo R, Guijarro A, Vacondio F, Duranti A, et al. (2010). Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nat Neurosci 13: 1265-1270.
14. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB, (1996). Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384: 83-87. (Pubitemid 26374593)
15. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, et al. (2001). Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A 98: 9371-9376. (Pubitemid 32743923)
16. Di Marzo V, (2008). Targeting the endocannabinoid system: to enhance or to reduce? Nat Rev Drug Discov 7: 438-455. (Pubitemid 351649182)
17. Di Marzo V, (2009). The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacol Res 60: 77-84.
18. Di Marzo V, Bisogno T, De Petrocellis L, Melck D, Orlando P, Wagner JA, et al. (1999). Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur J Biochem 264: 258-267. (Pubitemid 29385890)
19. Falenski KW, Thorpe AJ, Schlosburg JE, Cravatt BF, Abdullah RA, Smith TH, et al. (2010). FAAH-/- mice display differential tolerance, dependence, and cannabinoid receptor adaptation after delta 9-tetrahydrocannabinol and anandamide administration. Neuropsychopharmacology 35: 1775-1787.
20. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, et al. (1995). Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232: 54-61.
21. Ghosh S, Wise LE, Chen Y, Gujjar R, Mahadevan A, Cravatt BF, et al. (2013). The monoacylglycerol lipase inhibitor JZL184 suppresses inflammatory pain in the mouse carrageenan model. Life Sci 92: 498-505.
22. Goparaju SK, Ueda N, Taniguchi K, Yamamoto S, (1999). Enzymes of porcine brain hydrolyzing 2-arachidonoylglycerol, an endogenous ligand of cannabinoid receptors. Biochem Pharmacol 57: 417-423. (Pubitemid 29065290)
23. Guindon J, Hohmann AG, (2009). The endocannabinoid system and pain. CNS Neurol Disord Drug Targets 8: 403-421.
24. Guindon J, Guijarro A, Piomelli D, Hohmann AG, (2011). Peripheral antinociceptive effects of inhibitors of monoacylglycerol lipase in a rat model of inflammatory pain. Br J Pharmacol 163: 1464-1478.
25. Guindon J, Lai Y, Takacs SM, Bradshaw HB, Hohmann AG, (2013). Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment. Pharmacol Res 67: 94-109.
26. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC, (1991). Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11: 563-583.
27. Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley D, Mangieri R, et al. (2005). An endocannabinoid mechanism for stress-induced analgesia. Nature 435: 1108-1112. (Pubitemid 40910518)
28. Jayamanne A, Greenwood R, Mitchell VA, Aslan S, Piomelli D, Vaughan CW, (2006). Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol 147: 281-288. (Pubitemid 43214685)
29. Jhaveri MD, Richardson D, Kendall DA, Barrett DA, Chapman V, (2006). Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain. J Neurosci 26: 13318-13327. (Pubitemid 46011642)
30. Kathuria S, Gaetani S, Fegley D, Valinoc F, Duranti A, Tontini A, et al. (2003). Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9: 76-81. (Pubitemid 36098263)
31. Khasabova IA, Chandiramani A, Harding-Rose C, Simone DA, Seybold VS, (2011). Increasing 2-arachidonoyl glycerol signaling in the periphery attenuates mechanical hyperalgesia in a model of bone cancer pain. Pharmacol Res 64: 60-67.
32. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
33. Kinsey SG, Long JZ, O'Neal ST, Abdullah RA, Poklis JL, Boger DL, et al. (2009). Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain. J Pharmacol Exp Ther 330: 902-910.
34. Kinsey SG, Long JZ, Cravatt BF, Lichtman AH, (2010). Fatty acid amide hydrolase and monoacylglycerol lipase inhibitors produce anti-allodynic effects in mice through distinct cannabinoid receptor mechanisms. J Pain 11: 1420-1428.
35. Kinsey SG, Nomura DK, O'Neal ST, Long JZ, Mahadevan A, Cravatt BF, et al. (2011). Inhibition of monoacylglycerol lipase attenuates nonsteroidal anti-inflammatory drug-induced gastric hemorrhages in mice. J Pharmacol Exp Ther 338: 795-802.
36. Kinsey SG, Wise LE, Ramesh D, Abdullah R, Selley DE, Cravatt BF, et al. (2013). Repeated low dose administration of the monoacylglycerol lipase Inhibitor JZL184 retains CB1 receptor functional effects. J Pharmacol Exp Ther 345: 492-501.
37. La Rana G, Russo R, Campolongo P, Bortolato M, Mangieri RA, Cuomo V, et al. (2006). Modulation of neuropathic and inflammatory pain by the endocannabinoid transport inhibitor AM404 [N-(4-hydroxyphenyl)-eicosa-5,8,11,14- tetraenamide. J Pharmacol Exp Ther 317: 1365-1371. (Pubitemid 43764143)
38. Lichtman AH, Shelton CC, Advani T, Cravatt BF, (2004a). Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain 109: 319-327. (Pubitemid 38638709)
39. Lichtman AH, Leung D, Shelton CC, Saghatelian A, Hardouin C, Boger DL, et al. (2004b). Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther 311: 441-448. (Pubitemid 39391527)
40. Lichtman AH, Blankman JL, Cravatt BF, (2010). Endocannabinoid overload. Mol Pharmacol 78: 993-995.
41. Liu W, Okajima K, Murakami K, Harada N, Isobe H, Irie T, (1998). Role of neutrophil elastase in stress-induced gastric mucosal injury in rats. J Lab Clin Med 132: 432-439. (Pubitemid 28552101)
42. Long JZ, Li W, Booker L, Burston JJ, Kinsey SG, Schlosburg JE, et al. (2009a). Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol 5: 37-44.
43. Long JZ, Nomura DK, Cravatt BF, (2009b). Characterization of monoacylglycerol lipase inhibition reveals differences in central and peripheral endocannabinoid metabolism. Chem Biol 16: 744-753.
44. Long JZ, Nomura DK, Vann RE, Walentiny DM, Booker L, Jin X, et al. (2009c). Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proc Natl Acad Sci U S A 106: 20270-20275.
45. Martin BR, Compton DR, Thomas BF, Prescott WR, Little PJ, Razdan RK, et al. (1991). Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav 40: 471-478.
46. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
47. Naidu PS, Booker L, Cravatt BF, Lichtman AH, (2009). Synergy between enzyme inhibitors of fatty acid amide hydrolase and cyclooxygenase in visceral nociception. J Pharmacol Exp Ther 329: 48-56.
48. Naidu PS, Kinsey SG, Guo TL, Cravatt BF, Lichtman AH, (2010). Regulation of inflammatory pain by inhibition of fatty acid amide hydrolase. J Pharmacol Exp Ther 334: 182-190.
49. National Research Council (2011). Guide for the Care and Use of Laboratory Animals. National Academies Press: Washington, DC.
50. Nomura DK, Morrison BE, Blankman JL, Long JZ, Kinsey SG, Marcondes MC, et al. (2011). Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 334: 809-813.
51. Okine BN, Norris LM, Woodhams S, Burston J, Patel A, Alexander SP, et al. (2012). Lack of effect of chronic pre-treatment with the FAAH inhibitor URB597 on inflammatory pain behaviour: evidence for plastic changes in the endocannabinoid system. Br J Pharmacol 167: 627-640.
52. Petrosino S, Di Marzo V, (2010). FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Curr Opin Investig Drugs 11: 51-62.
53. Ramesh D, Ross GR, Schlosburg JE, Owens RA, Abdullah RA, Kinsey SG, et al. (2011). Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated opioid withdrawal symptoms in mice. J Pharmacol Exp Ther 339: 173-185.
54. Russo EB, (2007). History of cannabis and its preparations in saga, science, and sobriquet. Chem Biodivers 4: 1614-1648. (Pubitemid 47381191)
55. Russo EB, Jiang HE, Li X, Sutton A, Carboni A, del Bianco F, et al. (2008). Phytochemical and genetic analyses of ancient cannabis from Central Asia. J Exp Bot 59: 4171-4182.
56. Russo R, Loverme J, La Rana G, Compton TR, Parrott J, Duranti A, et al. (2007). The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3′-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. J Pharmacol Exp Ther 322: 236-242. (Pubitemid 46956375)
57. Schlosburg JE, Blankman JL, Long JZ, Nomura DK, Pan B, Kinsey SG, et al. (2010). Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat Neurosci 13: 1113-1119.
58. Sciolino NR, Zhou W, Hohmann AG, (2011). Enhancement of endocannabinoid signaling with JZL184, an inhibitor of the 2-arachidonoylglycerol hydrolyzing enzyme monoacylglycerol lipase, produces anxiolytic effects under conditions of high environmental aversiveness in rats. Pharmacol Res 64: 226-234.
59. Spradley JM, Guindon J, Hohmann AG, (2010). Inhibitors of monoacylglycerol lipase, fatty-acid amide hydrolase and endocannabinoid transport differentially suppress capsaicin-induced behavioral sensitization through peripheral endocannabinoid mechanisms. Pharmacol Res 62: 249-258.
60. Starowicz K, Przewlocka B, (2012). Modulation of neuropathic-pain-related behaviour by the spinal endocannabinoid/endovanilloid system. Philos Trans R Soc Lond B Biol Sci 367: 3286-3299.
61. Walentiny DM, Vann RE, Mahadevan A, Kottani R, Gujjar R, Wiley JL, (2013). Novel 3-substituted rimonabant analogs lack Δ(9)- tetrahydrocannabinol-like abuse-related behavioral effects in mice. Br J Pharmacol 169: 10-20.
62. Wise LE, Cannavacciulo R, Cravatt BF, Martin BF, Lichtman AH, (2008). Evaluation of fatty acid amides in the carrageenan-induced paw edema model. Neuropharmacology 54: 181-188. (Pubitemid 350299403)
63. Woodhams SG, Wong A, Barrett DA, Bennett AJ, Chapman V, Alexander SP, (2012). Spinal administration of the monoacylglycerol lipase inhibitor JZL184 produces robust inhibitory effects on nociceptive processing and the development of central sensitization in the rat. Br J Pharmacol 167: 1609-1619.